Cyclana Bio received UK NHS approval to start its Predicting Endometriosis Mechanisms and Populations (PEMP) observational study aimed at identifying endometriosis biomarkers and druggable targets. The company secured Health Research Authority (HRA) and Research Ethics Committee approval to enroll 500 patients. Cyclana plans to collect both biopsy- and menstrual-fluid-derived samples to build in vitro 3D disease models and compare tissue-level dynamics between patients with and without endometriosis. The effort is intended to prioritize targets and assess whether a single treatment strategy is feasible or whether individualized approaches are needed. Cyclana noted the study will be funded through a £5 million pre-seed round and is already recruiting at Peterborough City Hospital and Rosie Hospital in Cambridge.